Dextromethorphan/bupropion · Auvelity

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Alzheimer's Disease Agitation

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Company guidance: topline data expected 2H 2027 (NCT07766655; Axsome Therapeutics, 2 Nov 2026). “Evaluating AXS-05 as a treatment for smoking cessation Key eligibility criteria 18-65 years of age Primary endpoint Change from baseline in smoking abstinence SUMMIT Phase 3 trial 26 AXS-05 Bupropion Placebo 1:1:1 R Screening Double-blind phase (12 weeks) Follow-up Baseline Topline results anticipated 2H 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Alzheimer's Disease Agitation
NCT06736509 · Axsome Therapeutics, Inc.
2024-11-21 – 2025-04-25 · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
What this study did
Major Depressive Disorder
NCT04039022 · Axsome Therapeutics, Inc.
2019-07-08 – 2020-10-23 · Major Depressive Disorder, Treatment Resistant Depression, Depression
What this study did
Other / comorbidity
NCT07766655 · Axsome Therapeutics, Inc.
2026-08-27 – 2027-12 · Smoking Cessation
What this study did
Phase 2/3 (1)
Alzheimer's Disease Agitation
Phase 2 (6)
Major Depressive Disorder
NCT07523048 · Roger McIntyre
2025-11-21 – 2027-01 · Major Depressive Disorder (MDD)
What this study did
NCT04634669 · Axsome Therapeutics, Inc.
2020-09-23 – 2022-03-04 · Treatment Resistant Depression, Major Depressive Disorder
What this study did
NCT04608396 · Axsome Therapeutics, Inc.
2020-08-13 – 2021-07-30 · Treatment Resistant Depression, Major Depressive Disorder
What this study did
NCT04971291 · Axsome Therapeutics, Inc.
2021-04-14 – 2021-07 · Major Depressive Disorder, Treatment Resistant Depression
What this study did
Other / comorbidity
NCT03471767 · James Davis
2018-03-25 – 2019-03-31 · Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05976646 · Virginia Commonwealth University
2023-09-18 – 2025-07-09 · Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
What this study did
Phase 4 (1)
Major Depressive Disorder
NCT06223880 · Axsome Therapeutics, Inc.
2023-12-27 – 2026-03 · Major Depressive Disorder
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Alzheimer's Disease Agitation: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dextromethorphan / Bupropion (Auvelity): this drugApprovedSmall moleculeDopamine/norepinephrine transporter, sigma-1/NMDAReliable signal
NCT05557409: Change in CMAI total score, baseline to Week 5 (ADVANCE-2): -13.8 points AXS-05 vs -12.6 points placebo; did not reach statistical significance missed
NCT03226522: Change in CMAI Total Score (5 weeks): AXS-05 -15.4 score on a scale (Standard Error 1.25) vs Bupropion -10 score on a scale (Standard Error 3.02) vs Placebo -11.5 score on a scale (Standard Error 1.1)
Naltrexone / Bupropion (Contrave)
Approved(overall)
Small moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporter
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)
Phase 3(overall; approved for another use)
Small moleculeAlpha-2 adrenergic receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
DeulumateperonePhase 2Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
AVP-786
Discontinued
Combinationsigma-1/NMDA
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Auvelity (Dextromethorphan/bupropion) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3Smoking CessationRecruiting
Est. primary completion 2027-12 · NCT07766655 · CT.gov ↗

Company guidance: topline data expected 2H 2027 (Axsome Therapeutics, 2 Nov 2026). “Evaluating AXS-05 as a treatment for smoking cessation Key eligibility criteria 18-65 years of age Primary endpoint Change from baseline in smoking abstinence SUMMIT Phase 3 trial 26 AXS-05 Bupropion Placebo 1:1:1 R Screening Double-blind phase (12 weeks) Follow-up Baseline Topline results anticipated 2H 2027” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2026ApprovalFDA approves Auvelity for Alzheimer's disease agitation
US, FDA · Axsome Therapeutics · Source ↗
31 December 2025Priority reviewFDA accepts AXS-05 sNDA with Priority Review
US, FDA · Axsome Therapeutics · Source ↗
30 December 2024Topline resultACCORD-2 Phase 3 met primary endpoint
Axsome Therapeutics · Source ↗